2-chloro-8-methyl-9-(propan-2-yl)-9H-purine | 1044770-67-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-chloro-8-methyl-9-(propan-2-yl)-9H-purine
• 英文别名: 2-chloro-8-methyl-9-propan-2-ylpurine
• CAS: 1044770-67-3
• 化学式: C₉H₁₁ClN₄
• 分子量: 210.66
• InChiKey: IXLPNJSVQKKBKZ-UHFFFAOYSA-N

物化性质

• 密度：
  1.38±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF
  申请人：Shanghai Xunhe Pharmaceutical Technology Co., Ltd.

  公开号：EP3444246A1

  公开（公告）日：2019-02-20

  The present invention relates to a 2,4-disubstituted pyrimidine derivative and the use thereof as a therapeutically effective cyclin-dependent kinase(CDK) inhibitor. In particular, the present invention relates to the use of a new 2,4-disubstituted pyrimidine derivativeas shown in formula (I) and a pharmaceutical composition thereof as a selective CDK4/6inhibitor in preventing or treating diseases related to CDK4/6.

  本发明涉及一种2,4-二取代嘧啶衍生物及其作为治疗有效的细胞周期蛋白依赖性激酶（CDK）抑制剂的用途。特别是，本发明涉及一种如式（I）所示的新型 2,4-二取代嘧啶衍生物及其药物组合物作为选择性 CDK4/6 抑制剂在预防或治疗与 CDK4/6 有关的疾病中的用途。
• 2,4-disubstituted pyrimidines as CDK inhibitors
  申请人：Shanghai Xunhe Pharmaceutical Technology Co. Ltd.

  公开号：US10464927B2

  公开（公告）日：2019-11-05

  The present disclosure relates to a 2,4-disubstituted pyrimidine derivative and the use thereof as a therapeutically effective cyclin-dependent kinase (CDK) inhibitor. In particular, the present disclosure relates to the use of a new 2,4-disubstituted pyrimidine derivatives shown in formula (I) and a pharmaceutical composition thereof as a selective CDK4/6 inhibitor in preventing or treating diseases related to CDK4/6.

  本公开涉及一种2,4-二取代嘧啶衍生物及其作为治疗有效的细胞周期蛋白依赖性激酶（CDK）抑制剂的用途。特别是，本公开涉及式（I）所示的一种新的2,4-二取代嘧啶衍生物及其药物组合物作为选择性CDK4/6抑制剂在预防或治疗与CDK4/6有关的疾病中的用途。
• 2,4-Disubstituted Pyrimidine Derivative as CDK Inhibitor and Use Thereof
  申请人：Shanghai Xunhe Pharmaceutical Technology Co. Ltd.

  公开号：US20190071427A1

  公开（公告）日：2019-03-07

  The present disclosure relates to a 2,4-disubstituted pyrimidine derivative and the use thereof as a therapeutically effective cyclin-dependent kinase (CDK) inhibitor. In particular, the present disclosure relates to the use of a new 2,4-disubstituted pyrimidine derivatives shown in formula (I) and a pharmaceutical composition thereof as a selective CDK4/6 inhibitor in preventing or treating diseases related to CDK4/6.